Laboratory-Based Assessment of Plasma Lipids and Lipopoteins for the Classification of Familial Hypercholesterolemic and Hypertriglyceridemic States

Pierre N. M. Demacker

doi:10.1055/s-2004-822982

Seminars in Vascular Medicine, Table of Contents

Semin Vasc Med 2004; 4(1): 13-22
DOI: 10.1055/s-2004-822982

Laboratory-Based Assessment of Plasma Lipids and Lipopoteins for the Classification of Familial Hypercholesterolemic and Hypertriglyceridemic States

Pierre N.M Demacker¹

¹Laboratory of General Internal Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands

Abstract

Laboratory-based coronary heart disease risk assessment classically involves measurement of lipids and lipoproteins. In this review, information is provided on the methods commonly used in laboratories for the diagnosis of hyperlipidemia, including aspects of precision and accuracy. The latter, when fulfilled, allows the use of uniform reference values. Special attention is paid to the risk estimation using apolipoprotein B and lipoprotein(a) measurement. The overall aim of this review is to simplify the laboratory-based risk estimation for coronary heart disease and to provide help in interpreting the results for effective prevention and treatment of this complex disease.

KEYWORDS

Hyperlipoproteinemias - lipoprotein analysis - apolipoprotein B - coronary heart disease risk profile - lipoprotein (a)

Full Text

References

REFERENCES

1 The 24-hour standing test of plasma in the refrigerator is a commonly used, though insensitive, test to detect chylomicrons, either in nonfasting plasma or in plasma of subjects with elevations of both chylomicrons and VLDL caused by lipolysis problems. In the case of exogeneous hyperchylomicronemia (Fredrickson's type I hyperlipoproteinemia), the 24-hour standing test shows a clear, yellow-colored plasma with a broad, creamy layer at the meniscus.

1 Fredrickson D S, Levy R I, Lees R S. Fat transport in lipoproteins. New Engl J Med. 1967; 276 34-44 94-103 148-156 215-226 273-281
2 Cole T G, Klotzsch G, McNamara J R. Measurement of triglyceride concentration. In: Rifai N and Warnick GR Laboratory Measurement of Lipids, Lipoproteins and Apolipoproteins. Washington, DC; AACC Press 1994: 81-90
3 Klotzsch S G, McNamara J R. Triglyceride measurements: a review of methods and interferences. Clin Chem. 1990; 36 1605-1613
4 Shephard M D, Whiting M J. Falsely low estimation of triglycerides in lipemic plasma by triglyceride method with modified Trinder's chromogen. Clin Chem. 1990; 36 325-329
5 Cobbaert C, Weykamp C, Baadenhuijsen H, Kuypers A, Lindemans J, Jansen R. Selection, preparation and characterization of commutable frozen human serum pools as potential secondary reference material for lipid and apolipoprotein measurement: Study within the framework of the Dutch project Calibration 2000. Clin Chem. 2002; 48 1526-1538
6 Artiss J D, Feldbruegge D H, Kroll M H et al.. Measurement of cholesterol concentration. In: Rifai N and Warnick GR Laboratory Measurement of Lipids, Lipoproteins and Apolipoproteins. Washington, DC; AACC Press 1994: 65-80
7 Demacker P N, Schade R W, Jansen R T, Van't Laar A. Intra-individual variation of serum cholesterol, triglycerides and high-density lipoprotein-cholesterol in normal humans. Atherosclerosis. 1982; 45 259-266
8 Rifai N, Dufour D R, Cooper G R. Preanalytical variation in lipid, lipoprotein and apolipoprotein testing. In: Rifai N and Warnick GR Laboratory Measurement of Lipids, Lipoproteins and Apolipoproteins. Washington, DC; AACC Press 1994: 43-64
9 Havel R J, Eder H A, Bragdon J H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955; 34 1345-1354
10 Warnick G R, Mayfield C, Albers J J, Hazzard W R. Gel isoelectric focusing method for specific diagnosis of familial hyperlipoproteinemia type 3. Clin Chem. 1979; 25 279-284
11 Demacker P NM, Vos-Janssen H E, Jansen A P, Van't Laar A. Evaluation of the dual precipitation method by comparison with the ultracentrifugation method for measurement of lipoproteins in serum. Clin Chem. 1977; 23 1238-1244
12 Wiebe D A, Warnick G R. Measurement of high-density lipoprotein cholesterol concentration. In: Rifai N and Warnick GR Laboratory Measurement of Lipids, Lipoproteins and Apolipoproteins. Washington, DC; AACC Press 1994: 91-107
13 Demacker P NM, Hijmans A GM, Vos-Janssen H E, Van't Laar A, Jansen A P. A study of the use of polyethylene glycol in estimating cholesterol in high density lipoprotein. Clin Chem. 1980; 26 1775-1794
14 Demacker P NM, Hessels M, Toenhake-Dijkstra H, Baadenhuijsen H. Precipitation methods for high-density lipoprotein cholesterol measurement compared, and final evaluation under routine operating conditions of a method with a low sample-to-reagent ratio. Clin Chem. 1997; 43 663-668
15 Okada M, Matsui H, Ito Y, Fujiwara A. Direct measurement of HDL-cholesterol: method eliminating apolipoprotein E-rich particles. J Clin Lab Anal. 2001; 15 223-229
16 Warnick G, Benderson J, Albers J J. Dextran sulfate-Mg²⁺ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem. 1982; 28 1379-1388
17 Roberts W L, Leary E T, Lambert T L, Moulton L, Goestch J L. Falsely low direct HDL-cholesterol results in a patient with dysbetalipopreinemia. Clin Chem. 2000; 46 560-562
18 Cole T G, Nowatzke W L, Bisgaier C L, Krause B R. Method-dependent changes in “HDL-cholesterol” with recombinant apolipoprotein A-1_Milano infusion in healthy volunteers. Clin Chem. 2002; 48 680-681
19 Cobbaert C M, Luderer T KJ. Total error of Roche direct HDL-cholesterol reagent and calibrator across 31 lot combinations: A 2-year experience. Clin Chem. 2000; 46 133-134
20 De Keijzer M H, Elbers D, Baadenhuijsen H, Demacker P N. Evaluation of five different high-density lipoprotein cholesterol assays: the most precise are not the most accurate. Ann Clin Biochem. 1999; 36 168-175
21 Friedewald W T, Levy R I, Fredrickson D S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the ultracentrifuge. Clin Chem. 1972; 18 499-501
22 Demacker P NM, Hijmans A G, Brenninkmeijer B J, Jansen A P, Van't Laar A. Five methods for determination of low-density lipoproteins compared. Clin Chem. 1984; 30 1797-1798
23 Hattori Y, Suzaki M, Tsushima M et al.. Development of approximate formula for LDL-cholesterol, LDL-apo B and LDL-apo B as indices of hyperapobetalipoproteinemia and small dense LDL. Atherosclerosis. 1998; 138 289-299
24 Demacker P NM, Toenhaake-Dijkstra H, de Rijke Y, Stalenhoef A FH, Stuyt P MJ, Willems H L. On the presumed inaccuracy of the Friedewald formula in hypertriglyceridemic plasma: a role for imprecise analysis?. Clin Chem. 1996; 42 1491-1494
25 Schaefer E J, McNamara J R. Overview of the diagnosis and treatment of lipid disorders. In: Rifai N and Warnick GR Laboratory Measurement of Lipids, Lipoproteins and Apolipoproteins. Washington, DC; AACC Press 1994: 21-43
26 Demacker P NM, Veerkamp M J, Bredie S JH, Marcovina S M, de Graaf J, Stalenhoef A FH. Comparison of the measurement of lipids and lipoproteins versus assay of apolipoprotein B for estimation of coronary heart disease risk: a study in familial combined hyperlipidemia. Atherosclerosis. 2000; 153 483-490
27 Wu L H, Wu J T, Hopkins P N. Apolipoprotein E: Laboratory determination and clinical significance. In: Rifai N and Warnick GR Laboratory Measurement of Lipids, Lipoproteins and Apolipoproteins. Washington, DC; AACC Press 1994: 279-305
28 Wiegman A, Rodenburg J, de Jongh S et al.. Family history and cardiovascular risk in familial hypercholesterolemia: data in more than 1000 children. Circulation. 2003; 107 1473-1478
29 Fredrickson D S, Morganroth J, Levy R I. Type III hyperlipoproteinemia, an analysis of two contemporary definitions. Ann Intern Med. 1975; 82 150-157
30 Demacker P NM, Vos-Janssen H E, Stuyt P MJ, Schade R WB, Jansen A P, Van't Laar A. Application and comparison of different criteria for the diagnosis of type III hyperlipoproteinemia. Clin Chem. 1978; 24 1445-1451
31 , Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA. 2001; 285 2486-2497
32 Sniderman A D, Wolfson C, Teng B, Franklin F A, Bachorik P S, Kwiterovich Jr P O. Association of hyperapobetalipoproteinemia with endogeneous hyper-triglyceridemia and atherosclerosis. Ann Intern Med. 1982; 97 833-839
33 Sniderman A D, Furberg C D, Keech A et al.. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet. 2003; 361 777-780
34 Marcovina S M, Albers J J, Kenned H, Mei J V, Henderson L O, Hannon W H. International Federation of Clinical Chemistry standardization project for measurements of apolipoprotein A-1 and B. IV. Comparability of apo B values by use of international reference material. Clin Chem. 1994; 40 586-592
35 Williams K, Sniderman A D, Sattar N, D'Agostino R, Wagenknecht L E, Haffner S M. Comparison of the associations of apolipoprotein B and low density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2003; 108 2312-2316
36 Kroll M H, Cole T G, Rifai N, Cooper G, Warnick J R, Jialal I. Standardization of lipoprotein reporting. Am J Clin Pathol. 2000; 114 696-702
37 Scanu A M. Lipoprotein(a), Friedewald formula and NCEP guidelines. Am J Cardiol. 2001; 87 608-609
38 Tate J R, Rifai N, Berg K et al.. International Federation of Clinical Chemistry standardization project for the measurement of lipoprotein(a). Phase 1. Evaluation of the analytical performance of lipoprotein(a) assay systems and commercial calibrators. Clin Chem. 1998; 44 1629-1640
39 Marcovina S M, Albers J J, Scanu A M et al.. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem. 2000; 46 1956-1967
40 Ameimiya H, Arinami T, Kikuchi S et al.. Apolipoprotein(a) and pentanucleotide repeat polymorphism is associated with the degree of atherosclerosis in coronary heart disease. Atherosclerosis. 1996; 123 181-191
41 Holmer S R, Hengstenberg C, Kraft H G et al.. Association of polymorphisms of apolipoprotein(a) gene with lipoprotein(a) levels and myocardial infarction. Circulation. 2003; 107 696-701
42 Hutchison B, Birch S, Evans C E et al.. Screening for hypercholesterolaemia in primary care: randomised controlled trial of postal questionnaire appraising risk of coronary heart disease. BMJ. 1998; 316 1208-1212